Compare ICICI Bank Limited Common Stock (IBN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ICICI Bank Limited Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? ICICI Bank Limited Common Stock trades at $28.82 (market cap $101.96B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: ICICI Bank Limited Common Stock is far larger — about 13.6× Spyre Therapeutics Inc. Common Stock's market cap, and ICICI Bank Limited Common Stock pays a 0.88% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ICICI Bank Limited Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IBN | SYRE | |
|---|---|---|
Market Cap | $101.96B | $7.52B |
Volume | 5,301,480 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $32.94 | $108.92 |
52-Week Low | $25.20 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $9.90T | $6.52B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBN trades at $28.54, up 1.75% today, showing strong momentum with recent earnings beats in Q1 and Q2 2026. The stock maintains robust fundamentals including a 24.8% net income margin and 15.8% ROE, supported by $2.05T revenue in 2025. Technical indicators show bearish signals despite unanimous analyst buy ratings, with RSI suggesting potential overbought conditions near current levels.
The outlook remains positive given strong profitability metrics and analyst consensus, but technical weakness and high valuation multiples (P/E 17.85, P/S 4.43) present near-term risks. Investors should monitor Q3 2026 earnings results against expectations of $0.40 EPS for continued fundamental confirmation.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ICICI Bank Limited Common Stock
ICICI Bank is an Indian financial services company providing banking, lending, cards, insurance, and investment products. It serves retail, business, and corporate customers.
Read more on IBN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
